Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Pyxis Oncology, Inc. has received a consensus rating of "Moderate Buy" from five research firms, with an average 12-month price target of $8.67.
• The company reported a loss of ($0.30) earnings per share for the latest quarter, aligning this figure with an expected annual loss of ($1.04) per share.
• Institutional investors hold approximately 39.09% of Pyxis Oncology's stock, with notable increases in holdings from firms like Bank of America and Barclays.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $7.75.

A number of brokerages have recently weighed in on PYXS. Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 24th. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Zacks Research upgraded Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Finally, Guggenheim assumed coverage on Pyxis Oncology in a research note on Wednesday. They set a "buy" rating and a $5.00 target price on the stock.

Pyxis Oncology Trading Up 9.5%

Shares of NASDAQ:PYXS traded up $0.14 on Friday, hitting $1.61. The company had a trading volume of 1,214,067 shares, compared to its average volume of 492,151. The stock has a market cap of $99.85 million, a price-to-earnings ratio of -1.01 and a beta of 1.14. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39. The stock has a 50 day moving average price of $1.19 and a 200 day moving average price of $1.15.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. Sell-side analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently added to or reduced their stakes in PYXS. Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after purchasing an additional 1,043,228 shares in the last quarter. Ridgeback Capital Investments L.P. acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $560,000. Jane Street Group LLC acquired a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $370,000. Pier 88 Investment Partners LLC boosted its holdings in shares of Pyxis Oncology by 296.6% in the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock valued at $383,000 after purchasing an additional 292,370 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock valued at $939,000 after purchasing an additional 219,100 shares in the last quarter. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.